RAPT Therapeutics Reports Second Quarter 2025 Financial Results

Core Insights - RAPT Therapeutics reported a productive first half of 2025 with key achievements and upcoming catalysts anticipated in the second half of the year [2] - The company is on track to initiate a Phase 2b trial of RPT904 in food allergy and to report topline results from Jemincare's Phase 2 trials of RPT904 in CSU and asthma [2] - RAPT's financial results show a significant reduction in net loss compared to the previous year, indicating improved financial health [3][5] Financial Performance - The net loss for the second quarter of 2025 was $17.6 million, a decrease from $27.7 million in the second quarter of 2024 [3] - Research and development expenses for the second quarter of 2025 were $12.3 million, down from $22.6 million in the same period of 2024, primarily due to reduced costs in the development of certain drugs [4] - General and administrative expenses increased to $7.2 million in the second quarter of 2025 from $6.7 million in the same period of 2024, mainly due to higher consulting and facilities costs [5] Six-Month Overview - For the six months ended June 30, 2025, the net loss was $34.8 million, compared to $58.2 million for the same period in 2024 [5] - Research and development expenses for the first half of 2025 totaled $24.4 million, down from $47.4 million in the first half of 2024, reflecting a similar trend as seen in the second quarter [6] - General and administrative expenses remained flat at $14.4 million for both the first halves of 2025 and 2024 [7] Cash Position - As of June 30, 2025, RAPT had cash and cash equivalents and marketable securities totaling $168.9 million [7]